FDAnews
www.fdanews.com/articles/196172-nice-recommends-new-chemotherapy-free-treatment-for-lymphoma

NICE Recommends New ‘Chemotherapy-Free’ Treatment for Lymphoma

March 9, 2020

The National Institute for Health and Care Excellence (NICE) has recommended Celgene’s Revlimid (lenalidomide) with rituximab for patients with previously treated follicular lymphoma.

NICE’s review of clinical trial evidence found that when people take lenalidomide with rituximab, their follicular lymphoma does not progress as quickly as when they take rituximab with chemotherapy.

The combination costs more than rituximab with chemotherapy, but the cost-effectiveness estimate is within the range that NICE considers an acceptable use of NHS resources.

View today's stories